IL-15 agonist drug combinations for immune therapy

1. A method for treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of nogapendekin-alfa-inbakicept (NAI) prior to the subject undergoing a surgical procedure, but after or concomitantly with administration of a therapeutically effective amount of an antibiotic to the subject.

2. A method for treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of NAI after the subject has undergone a surgical procedure, and after or concomitantly with administration of a therapeutically effective amount of an antibiotic to the subject.

3. The method of claim 1 , wherein NAI is administered to the subject at least about 1 minute before the surgical procedure begins.

4. The method of claim 2 , wherein NAI is administered to the subject less than or equal to about 12 hours after the surgical procedure ends.

5. The method of claim 2 , wherein NAI is administered more than once.

6. The method of claim 5 , wherein NAI is administered twice per week.

7. The method of claim 5 , wherein NAI is administered three times or more per week.

8. The method of claim 2 , wherein the therapeutically effective amount of NAI is between about 10 μg and about 500 μg per dose.

9. The method of claim 8 , wherein the therapeutically effective amount of NAI is about 50 μg.

10. The method of claim 9 , wherein NAI is administered subcutaneously or intravenously.

11. The method of claim 9 , wherein the antibiotic is a cephalosporin.

12. The method of claim 9 , wherein the antibiotic is cefazolin.

13. The method of claim 2 , wherein the subject is a human.

14. A pharmaceutical combination comprising nogapendekin-alfa-inbakicept (NAI) and an antibiotic.

15. The pharmaceutical combination of claim 14 , wherein the antibiotic is a cephalosporin.

16. The pharmaceutical combination of claim 14 , wherein the antibiotic is selected from the group consisting of cefacetrile, cefadroxil, cefalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cefaclor, cefonicid, cefprozil, cefuroxime, cefuzonam, cefmetazole, cefotetan, cefoxitin, loracarbef, cefbuperazone, cefmetazole, cefotetan, cefoxitin, cefotiam, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefixime, cefmenoxime, cefodizime, cefotaxime, cefovecin, cefpimizole, cefpodoxime, cefteram, ceftibuten, ceftiofur, ceftiolene, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, oxacephem, latamoxef, cefclidine, cefepime, cefiderocol, cefluprenam, cefoselis, cefozopran, cefpirome, cefquinome, flomoxef, ceftobiprole, ceftaroline, ceftolozane, and a combination thereof.

17. The pharmaceutical combination of claim 14 , wherein the antibiotic is cefazolin.

18. The method of claim 1 , wherein NAI is administered more than once.

19. The method of claim 18 , wherein NAI is administered twice per week.

20. The method of claim 18 , wherein NAI is administered three times or more per week.

21. The method of claim 1 , wherein the therapeutically effective amount of NAI is between about 10 μg and about 500 μg per dose.

22. The method of claim 21 , wherein the therapeutically effective amount of NAI is about 50 μg.

23. The method of claim 22 , wherein NAI is administered subcutaneously or intravenously.

24. The method of claim 22 , wherein the antibiotic is a cephalosporin.

25. The method of claim 22 , wherein the antibiotic is cefazolin.

26. The method of claim 1 , wherein the subject is a human.